Related Experiment Video
Updated: Nov 27, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1
1Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Abstract:
Oncolytic virotherapy represents an ideal therapeutic platform for cancer in which natural or engineered viruses selectively replicate in and destroy tumor cells, whereas sparing normal cells. Oncolytic virotherapy is considered as a key contributor in modern immunotherapy. However, several challenges remain with regard to exploiting the potential of oncolytic viruses, such as the lack of biomarkers for precise treatment, the difficulty of systemic administration because of pre-existing neutralizing antibodies to popular oncolytic viral vectors in human serum and the lack of mature lyophilization technology for convenient transport and preservation of viral preparations. The M1 strain, which was isolated on Hainan Island of China in the 1960s, is a member of the alphavirus genus Togaviridae family. It was identified as a novel oncolytic virus in 2014. During the development of M1 virus, many challenges have been overcome: several biomarkers have been identified for precise treatment; systematic administration of M1 is suitable and feasible because of the extremely low percentage of pre-existing neutralizing antibodies in the general population, and a lyophilized powder that maintains high biological stability has been developed. This review provides an encyclopedia of studies supporting M1 as an oncolytic virus, including the biological characteristics, tumor selectivity and its mechanism, tumor killing mechanism, combination therapy, and nonclinical pharmacokinetics of M1 virus. The future development direction of oncolytic virus M1 is also discussed at the end of the review.
Insights
Oncolytic virotherapy using the M1 virus shows promise for cancer treatment. Researchers have overcome challenges in administration and preservation, identifying biomarkers for precise application.
Area of Science:
- Oncolytic virotherapy
- Immunotherapy
- Virology
Background:
- Oncolytic viruses selectively destroy tumor cells, offering a promising cancer therapy.
- Challenges include lack of biomarkers, neutralizing antibodies, and stable preservation methods.
- The M1 strain, an alphavirus, was identified as a novel oncolytic virus in 2014.
Purpose of the Study:
- To review the biological characteristics and therapeutic potential of the M1 oncolytic virus.
- To highlight advancements in M1 virus development, addressing previous oncolytic virus challenges.
- To discuss future directions for M1 virus in cancer treatment.
Main Methods:
- Review of existing studies on M1 virus biological characteristics.
- Analysis of M1 virus tumor selectivity and killing mechanisms.
- Evaluation of M1 virus pharmacokinetics and combination therapy potential.
Main Results:
- M1 virus demonstrates tumor selectivity and effective tumor cell destruction.
- Biomarkers for precise M1 treatment have been identified.
- Systemic administration is feasible due to low pre-existing neutralizing antibodies.
- A stable lyophilized M1 virus preparation has been developed.
Conclusions:
- The M1 virus is a viable oncolytic virus with overcome developmental challenges.
- M1 virus offers potential for precise, systemically administered cancer immunotherapy.
- Further research into M1 virus combination therapies and clinical applications is warranted.
